We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

132 hedge funds and large institutions have $212M invested in Epizyme, Inc in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

496% more call options, than puts

Call options by funds: $6.45M | Put options by funds: $1.08M

85% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 20

14% more funds holding

Funds holding: 116132 (+16)

8% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 36

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

56% less capital invested

Capital invested by funds: $480M → $212M (-$268M)

Holders
132
Holders Change
+16
Holders Change %
+13.79%
% of All Funds
2.03%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
37
Increased
39
Reduced
36
Closed
20
Calls
$6.45M
Puts
$1.08M
Net Calls
+$5.37M
Net Calls Change
-$7.01M
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
76
Wells Fargo
California
$108K +$169K +43,127 +36,241%
VF
77
Virtu Financial
New York
$107K +$168K +42,750 New
VOYA Investment Management
78
VOYA Investment Management
Georgia
$89K -$6.95K -1,770 -5%
Walleye Capital
79
Walleye Capital
New York
$89K +$139K +35,478 New
ProShare Advisors
80
ProShare Advisors
Maryland
$87K +$4.99K +1,270 +4%
PP
81
PDT Partners
New York
$78K +$122K +31,115 New
CANY
82
Caxton Associates (New York)
New York
$76K +$119K +30,300 New
TRCT
83
Tower Research Capital (TRC)
New York
$72K +$47.1K +11,996 +72%
Citigroup
84
Citigroup
New York
$71K -$796K -202,629 -88%
Principal Financial Group
85
Principal Financial Group
Iowa
$70K -$46.3K -11,791 -30%
MLICM
86
Metropolitan Life Insurance Company (MetLife)
New York
$66.9K +$17.3K +4,410 +20%
Balyasny Asset Management
87
Balyasny Asset Management
Illinois
$65K +$102K +25,990 New
B
88
BP
United Kingdom
$62K
HP
89
Harbourvest Partners
Massachusetts
$62K
Mirae Asset Global Investments
90
Mirae Asset Global Investments
South Korea
$60K +$2.25K +574 +2%
JRP
91
Jasper Ridge Partners
California
$54K
Royal Bank of Canada
92
Royal Bank of Canada
Ontario, Canada
$52K +$40.8K +10,376 +99%
WMSA
93
Weiss Multi-Strategy Advisers
New York
$50K -$15.9K -4,037 -17%
ASRS
94
Arizona State Retirement System
Arizona
$48K -$707 -180 -0.9%
LPL Financial
95
LPL Financial
California
$46K -$59K -15,028 -45%
SOW
96
State of Wyoming
Wyoming
$46K -$1.72K -437 -2%
AQR Capital Management
97
AQR Capital Management
Connecticut
$46K +$71.7K +18,243 New
Group One Trading
98
Group One Trading
Illinois
$44K +$68.9K +17,539 New
SG Americas Securities
99
SG Americas Securities
New York
$43K -$91.1K -23,194 -58%
AB
100
Amalgamated Bank
New York
$40K -$904 -230 -1%

EPZM Hedge Fund Activity: Q4 2021 in Review

132 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2021, worth a combined $212M — down 56% from $480M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EPZM positions and 20 closed out — a net gain of 17 holders — while 39 added to existing stakes and 36 trimmed.

The largest buyer was Bank of America, adding an estimated $11.4M. The largest seller was Redmile Group, cutting an estimated $27.5M.

  • 132 institutional investors held Epizyme, Inc (EPZM) as of Q4 2021, up from 116 in Q3 2021.
  • Funds reported $212M of Epizyme, Inc stock for Q4 2021, down 56% quarter-over-quarter.
  • 37 funds opened new Epizyme, Inc positions in Q4 2021 and 20 closed out, a net change of +17 holders.
  • The largest Epizyme, Inc buyer in Q4 2021 was Bank of America, an estimated $11.4M added.
  • The largest Epizyme, Inc seller in Q4 2021 was Redmile Group, an estimated $27.5M sold.

Based on aggregated 13F filings for Q4 2021.